A more prolonged administration of IL-15 might have induced greater therapeutic effects albeit balanced by an increased risk of lymphoproliferative disorder or lymphoma, either of which was seen in the IL-15 transgenic mouse [32]. The gene discussed is IL15; the disease is lymphoma.